Drugs that contain Cobimetinib Fumarate
1. Drug name - COTELLIC
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7803839 | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
Nov, 2029
(7 years from now) | |
| US10478400 | GENENTECH INC | Immediate-release tablets containing combimetinib and methods of making and using the same |
Jun, 2036
(13 years from now) | |
| US10590102 | GENENTECH INC | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone |
Jun, 2036
(13 years from now) | |
| CN109053523A | GENENTECH INC | As Mek Inhibitors For The Treatment Of Proliferative Diseases Of Azetidine |
Oct, 2026
(4 years from now) | |
| CN109053523B | GENENTECH INC | Azdines As Mek Inhibitors For The Treatment Of Proliferative Diseases |
Oct, 2026
(4 years from now) | |
| CN104892582B | GENENTECH INC | As Arylmethylazetidine For Mek Inhibitor For Treating Proliferative Diseases |
Oct, 2026
(4 years from now) | |
| CN104892582A | GENENTECH INC | As Azetidine Mek Inhibitors For The Treatment Of Proliferative Diseases |
Oct, 2026
(4 years from now) | |
| CN101365676B | GENENTECH INC | Azetidines As Mek Inhibitors For The Treatment Of Proliferative Diseases |
Oct, 2026
(4 years from now) | |
| CN101365676A | GENENTECH INC | Azetidines As Mek Inhibitors For The Treatment Of Proliferative Diseases |
Oct, 2026
(4 years from now) | |
| CN103524392A | GENENTECH INC | Azetidines As Mek Inhibitors For The Treatment Of Proliferative Diseases |
Oct, 2026
(4 years from now) | |
| CN103524392B | GENENTECH INC | As Mek Inhibitors For The Treatment Of Proliferative Diseases Of Azetidine |
Oct, 2026
(4 years from now) | |
| CN108135854B | GENENTECH INC | Immediate Release Tablet Containing Medicine And Method For Forming Tablet |
Jun, 2036
(13 years from now) | |
| CN108135854A | GENENTECH INC | Drug-Containing Immediate Release Tablets And A Method Of Forming A Tablet |
Jun, 2036
(13 years from now) | |
| IN200802771P1 | GENENTECH INC | Mek Inhibitors And Methods Of Thier Use |
Oct, 2026
(4 years from now) | |
| IN313177B | GENENTECH INC | Mek Inhibitors And Methods Of Thier Use |
Oct, 2026
(4 years from now) | |
| EP1934174B1 | GENENTECH INC | Azetidines As Mek Inhibitors For The Treatment Of Proliferative Diseases |
Oct, 2026
(4 years from now) | |
| EP1934174A1 | GENENTECH INC | Azetidines As Mek Inhibitors For The Treatment Of Proliferative Diseases |
Oct, 2026
(4 years from now) | |
| EP3316867B1 | GENENTECH INC | Immediate-Release Tablets Containing A Drug And Processes For Forming The Tablets |
Jun, 2036
(13 years from now) | |
| EP3316867A1 | GENENTECH INC | Immediate-Release Tablets Containing A Drug And Processes For Forming The Tablets |
Jun, 2036
(13 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8362002 | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
Oct, 2026
(4 years from now) | |
| US11087354 | GENENTECH INC | Combination therapies |
Jun, 2034
(11 years from now) | |
Treatment: Method of using cobimetinib for the treatment of melanoma
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 20MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.